Menu Menu

News

Featured
COVID-19 Research Pipeline

71,455

Registered/ Published

3,208

Registered

369

Published

4,701

Registered
As at 22 July 2021
FILTERED BY > Convalescent plasma Clear filter

Guidelines update, v41.1

15 July, 2021
Version 41.1 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of six new studies on disease-modifying treatments. Convalescent plasma - two new studies comparing convalescent plasma to usual care in 912 and 160 patients with moderate-critical COVID-19 (Bégin et al.), (Sekine et al.) Hydroxychloroquine - one new study comparing hydroxychloroquine to usual care...
News

Guidelines update, v38.3

13 May, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   Convalescent plasma...
News

Guidelines update, v38.1

29 April, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   - Lopinavir-ritonavir...
News

Communique # 41

1 April, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Convalescent plasma recommendation changed to 'do not use' The Taskforce Disease Modifying and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique

Guidelines update, v35.2

11 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:   Tocilizumab - The reference for one included study (Wang et al.) was...
News

Guidelines update, v35.1

4 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The references for REMAP-CAP and COVACTA (Rosas et al.) trials have...
News